Which has stronger earnings and valuation, NUVB or LNTH?

Lantheus has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvation Bio $62.90M 33.44 -$204.63M -$0.43 N/A Lantheus $1.54B 4.48 $233.56M $4.15 25.55

Is NUVB or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Nuvation Bio's net margin of -102.06%. Lantheus' return on equity of 29.32% beat Nuvation Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -102.06% -44.10% -23.80% Lantheus 18.05% 29.32% 15.00%

Does the media prefer NUVB or LNTH?

In the previous week, Nuvation Bio had 1 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Nuvation Bio and 4 mentions for Lantheus. Nuvation Bio's average media sentiment score of 0.68 beat Lantheus' score of 0.46 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LEGN or NUVB?

In the previous week, Legend Biotech had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 6 mentions for Legend Biotech and 5 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.68 beat Legend Biotech's score of 0.18 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PTCT or NUVB?

In the previous week, PTC Therapeutics had 8 more articles in the media than Nuvation Bio. MarketBeat recorded 13 mentions for PTC Therapeutics and 5 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.68 beat PTC Therapeutics' score of 0.49 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NUVB or CNTA?

In the previous week, Nuvation Bio had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 5 mentions for Nuvation Bio and 3 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Nuvation Bio's score of 0.68 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NUVB or MIRM?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 5 mentions for Nuvation Bio. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat Nuvation Bio's score of 0.68 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nuvation Bio (NUVB) Competitors

$6.04 +0.28 (+4.86%)

Closing price 03:58 PM Eastern

Extended Trading

$6.02 -0.02 (-0.33%)

As of 07:51 PM Eastern

Compare

NUVB vs. LNTH, LEGN, PTCT, CNTA, and MIRM

Should you buy Nuvation Bio stock or one of its competitors? MarketBeat compares Nuvation Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvation Bio include Lantheus (LNTH), Legend Biotech (LEGN), PTC Therapeutics (PTCT), Centessa Pharmaceuticals (CNTA), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Nuvation Bio compare to Lantheus?

Nuvation Bio (NYSE:NUVB) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Nuvation Bio's net margin of -102.06%. Lantheus' return on equity of 29.32% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Lantheus	18.05%	29.32%	15.00%

In the previous week, Nuvation Bio had 1 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Nuvation Bio and 4 mentions for Lantheus. Nuvation Bio's average media sentiment score of 0.68 beat Lantheus' score of 0.46 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvation Bio currently has a consensus target price of $12.50, indicating a potential upside of 106.95%. Lantheus has a consensus target price of $101.86, indicating a potential downside of 3.94%. Given Nuvation Bio's higher probable upside, research analysts plainly believe Nuvation Bio is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lantheus has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	33.44	-$204.63M	-$0.43	N/A
Lantheus	$1.54B	4.48	$233.56M	$4.15	25.55

Summary

Lantheus beats Nuvation Bio on 9 of the 15 factors compared between the two stocks.

How does Nuvation Bio compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Nuvation Bio (NYSE:NUVB) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

In the previous week, Legend Biotech had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 6 mentions for Legend Biotech and 5 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.68 beat Legend Biotech's score of 0.18 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech has a net margin of -21.98% compared to Nuvation Bio's net margin of -102.06%. Legend Biotech's return on equity of -24.92% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Legend Biotech has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nuvation Bio has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.29	-$296.80M	-$0.68	N/A
Nuvation Bio	$62.90M	33.44	-$204.63M	-$0.43	N/A

Legend Biotech presently has a consensus target price of $60.23, indicating a potential upside of 105.57%. Nuvation Bio has a consensus target price of $12.50, indicating a potential upside of 106.95%. Given Nuvation Bio's higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Legend Biotech and Nuvation Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Nuvation Bio (NYSE:NUVB) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

PTC Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

PTC Therapeutics currently has a consensus price target of $91.36, indicating a potential upside of 11.23%. Nuvation Bio has a consensus price target of $12.50, indicating a potential upside of 106.95%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

PTC Therapeutics has higher revenue and earnings than Nuvation Bio. PTC Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.94	$682.64M	-$2.33	N/A
Nuvation Bio	$62.90M	33.44	-$204.63M	-$0.43	N/A

61.7% of Nuvation Bio shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, PTC Therapeutics had 8 more articles in the media than Nuvation Bio. MarketBeat recorded 13 mentions for PTC Therapeutics and 5 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.68 beat PTC Therapeutics' score of 0.49 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has a net margin of -22.58% compared to Nuvation Bio's net margin of -102.06%. Nuvation Bio's return on equity of -44.10% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Summary

Nuvation Bio beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Nuvation Bio compare to Centessa Pharmaceuticals?

Nuvation Bio (NYSE:NUVB) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

In the previous week, Nuvation Bio had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 5 mentions for Nuvation Bio and 3 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Nuvation Bio's score of 0.68 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Centessa Pharmaceuticals has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Nuvation Bio's return on equity of -44.10% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Nuvation Bio presently has a consensus target price of $12.50, suggesting a potential upside of 106.95%. Centessa Pharmaceuticals has a consensus target price of $41.33, suggesting a potential upside of 2.06%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Centessa Pharmaceuticals has lower revenue, but higher earnings than Nuvation Bio. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	33.44	-$204.63M	-$0.43	N/A
Centessa Pharmaceuticals	$15M	417.77	-$197.53M	-$1.79	N/A

Nuvation Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Nuvation Bio beats Centessa Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Nuvation Bio (NYSE:NUVB) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 5 mentions for Nuvation Bio. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat Nuvation Bio's score of 0.68 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio has a net margin of -102.06% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Nuvation Bio currently has a consensus price target of $12.50, suggesting a potential upside of 106.95%. Mirum Pharmaceuticals has a consensus price target of $139.80, suggesting a potential upside of 25.73%. Given Nuvation Bio's higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	33.44	-$204.63M	-$0.43	N/A
Mirum Pharmaceuticals	$521.31M	13.01	-$23.36M	-$13.61	N/A

Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

61.7% of Nuvation Bio shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Mirum Pharmaceuticals beats Nuvation Bio on 10 of the 17 factors compared between the two stocks.

Get Nuvation Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVB vs. The Competition

Export

Metric	Nuvation Bio	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$2.01B	$3.45B	$6.45B	$23.27B
Dividend Yield	N/A	2.30%	2.69%	4.07%
P/E Ratio	-14.05	11.07	21.07	28.29
Price / Sales	33.44	334.82	530.36	21.84
Price / Cash	N/A	128.56	44.82	24.45
Price / Book	6.86	8.29	10.79	4.64
Net Income	-$204.63M	$23.85M	$3.56B	$1.07B
7 Day Performance	18.01%	5.21%	1.67%	-1.04%
1 Month Performance	27.83%	2.19%	0.43%	0.18%
1 Year Performance	199.75%	60.99%	32.84%	24.25%

Nuvation Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVB Nuvation Bio	3.3352 of 5 stars	$6.04 +4.9%	$12.50 +107.0%	+195.4%	$2.01B	$62.90M	N/A	60
LNTH Lantheus	2.9347 of 5 stars	$104.67 +0.1%	$101.86 -2.7%	+34.1%	$6.80B	$1.54B	25.22	1,193
LEGN Legend Biotech	4.4042 of 5 stars	$35.48 -1.1%	$60.23 +69.8%	-13.7%	$6.66B	$1.03B	N/A	2,965
PTCT PTC Therapeutics	2.508 of 5 stars	$76.77 +2.2%	$91.36 +19.0%	+61.3%	$6.23B	$1.73B	N/A	1,410	News Coverage Insider Trade High Trading Volume
CNTA Centessa Pharmaceuticals	1.5817 of 5 stars	$39.76 +0.1%	$41.33 +4.0%	+223.3%	$6.14B	$15M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NUVB) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvation Bio (NUVB) Competitors

NUVB vs. LNTH, LEGN, PTCT, CNTA, and MIRM

How does Nuvation Bio compare to Lantheus?

Summary

How does Nuvation Bio compare to Legend Biotech?

Summary

How does Nuvation Bio compare to PTC Therapeutics?

Summary

How does Nuvation Bio compare to Centessa Pharmaceuticals?

Summary

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvation Bio (NUVB) Competitors

NUVB vs. LNTH, LEGN, PTCT, CNTA, and MIRM

How does Nuvation Bio compare to Lantheus?

Which has more risk and volatility, NUVB or LNTH?

Is NUVB or LNTH more profitable?

Does the media prefer NUVB or LNTH?

Do analysts prefer NUVB or LNTH?

Do institutionals and insiders believe in NUVB or LNTH?

Which has stronger earnings and valuation, NUVB or LNTH?

Summary

How does Nuvation Bio compare to Legend Biotech?

Does the media refer more to LEGN or NUVB?

Is LEGN or NUVB more profitable?

Which has more volatility & risk, LEGN or NUVB?

Do insiders & institutionals have more ownership in LEGN or NUVB?

Which has stronger valuation & earnings, LEGN or NUVB?

Do analysts prefer LEGN or NUVB?

Summary

How does Nuvation Bio compare to PTC Therapeutics?

Which has more risk & volatility, PTCT or NUVB?

Do analysts recommend PTCT or NUVB?

Which has stronger earnings & valuation, PTCT or NUVB?

Do insiders and institutionals believe in PTCT or NUVB?

Does the media favor PTCT or NUVB?

Is PTCT or NUVB more profitable?

Summary

How does Nuvation Bio compare to Centessa Pharmaceuticals?

Does the media favor NUVB or CNTA?

Is NUVB or CNTA more profitable?

Do analysts rate NUVB or CNTA?

Which has stronger earnings & valuation, NUVB or CNTA?

Which has more volatility and risk, NUVB or CNTA?

Do insiders and institutionals have more ownership in NUVB or CNTA?

Summary

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Does the media favor NUVB or MIRM?

Is NUVB or MIRM more profitable?

Do analysts prefer NUVB or MIRM?

Which has higher valuation & earnings, NUVB or MIRM?

Which has more volatility & risk, NUVB or MIRM?

Do institutionals & insiders have more ownership in NUVB or MIRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools